(UCB) UCB - BR
Sector: Healthcare | Industry: Biotechnology | Exchange: BR (Belgium) | Market Cap: 49.342m EUR | Total Return: 61.3% in 12m
Avg Turnover: 56.1M
Warnings
Choppy
Tailwinds
Confidence
UCB SA is a Brussels-based biopharmaceutical company specializing in the development and commercialization of treatments for neurology and immunology disorders. Its core portfolio includes Cimzia for inflammatory conditions and a suite of epilepsy medications such as Vimpat, Keppra, and Briviact. The company also maintains a presence in the allergy market with Zyrtec and Xyzal, while expanding into rare diseases and bone health through Evenity and Fintepla.
The pharmaceutical industry operates on a high-intensity R&D model where patent lifecycles and regulatory approvals dictate long-term revenue stability. UCB manages this through a robust pipeline targeting unmet needs in Alzheimer’s disease, lupus, and chronic obstructive pulmonary disease. Beyond drug development, the company diversifies its income streams by engaging in contract manufacturing services for third-party entities.
To better understand how these clinical developments impact long-term valuation, consider reviewing the detailed financial metrics on ValueRay.
- Bimzelx global rollout and label expansions drive immunology revenue growth
- Rare disease portfolio scaling offsets Keppra and Vimpat patent expirations
- Operating margins expand as R&D investment cycles peak and leverage improves
- Evenity market share gains in osteoporosis strengthen high-margin specialty sales
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: 21.35% < 20% (prev 20.46%; Δ 0.89% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.16b > Net Income 1.56b |
| Net Debt (-43.0m) to EBITDA (2.59b): -0.02 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.0m) vs 12m ago -4.82% < -2% |
| Gross Margin: 74.29% > 18% (prev 69.64%; Δ 4.66% > 0.5%) |
| Asset Turnover: 43.61% > 50% (prev 35.46%; Δ 8.14% > 0%) |
| Interest Coverage Ratio: 15.56 > 6 (EBIT TTM 1.96b / Interest Expense TTM 126.0m) |
| A: 0.09 (Total Current Assets 6.05b - Total Current Liabilities 4.40b) / Total Assets 18.2b |
| B: 0.48 (Retained Earnings 8.68b / Total Assets 18.2b) |
| C: 0.11 (EBIT TTM 1.96b / Avg Total Assets 17.8b) |
| D: 1.49 (Book Value of Equity 10.9b / Total Liabilities 7.29b) |
| Altman-Z'' = 4.46 = AA |
| DSRI: 1.08 (Receivables 1.79b/1.31b, Revenue 7.74b/6.15b) |
| GMI: 0.94 (GM 69.64% / 74.29%) |
| AQI: 0.90 (AQ_t 0.56 / AQ_t-1 0.62) |
| SGI: 1.26 (Revenue 7.74b / 6.15b) |
| TATA: -0.03 (NI 1.56b - CFO 2.16b) / TA 18.2b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at EUR 249.70 with a total of 436,117 shares traded.
Over the past week, the price has changed by -8.04%,
over one month by +8.39%,
over three months by -1.41% and
over the past year by +61.34%.
UCB has no consensus analysts rating.
P/E Trailing = 32.2388
P/E Forward = 24.1546
P/S = 6.3741
P/B = 4.5405
P/EG = 1.9325
Revenue TTM = 7.74b EUR
EBIT TTM = 1.96b EUR
EBITDA TTM = 2.59b EUR
Long Term Debt = 2.06b EUR (from longTermDebt, last quarter)
Short Term Debt = 62.0m EUR (from shortTermDebt, last quarter)
Debt = 2.43b EUR (from shortLongTermDebtTotal, last quarter) + Leases 182.0m
Net Debt = -43.0m EUR (calculated: Debt 2.43b - CCE 2.47b)
Enterprise Value = 49.3b EUR (49.3b + Debt 2.43b - CCE 2.47b)
Interest Coverage Ratio = 15.56 (Ebit TTM 1.96b / Interest Expense TTM 126.0m)
EV/FCF = 25.23x (Enterprise Value 49.3b / FCF TTM 1.95b)
FCF Yield = 3.96% (FCF TTM 1.95b / Enterprise Value 49.3b)
FCF Margin = 25.24% (FCF TTM 1.95b / Revenue TTM 7.74b)
Net Margin = 20.13% (Net Income TTM 1.56b / Revenue TTM 7.74b)
Gross Margin = 74.29% ((Revenue TTM 7.74b - Cost of Revenue TTM 1.99b) / Revenue TTM)
Gross Margin QoQ = 74.89% (prev 73.56%)
Tobins Q-Ratio = 2.71 (Enterprise Value 49.3b / Total Assets 18.2b)
Interest Expense / Debt = 5.19% (Interest Expense 126.0m / Debt 2.43b)
Taxrate = 14.49% (264.0m / 1.82b)
NOPAT = 1.68b (EBIT 1.96b * (1 - 14.49%))
Current Ratio = 1.38 (Total Current Assets 6.05b / Total Current Liabilities 4.40b)
Debt / Equity = 0.22 (Debt 2.43b / totalStockholderEquity, last quarter 10.9b)
Debt / EBITDA = -0.02 (Net Debt -43.0m / EBITDA 2.59b)
Debt / FCF = -0.02 (Net Debt -43.0m / FCF TTM 1.95b)
Total Stockholder Equity = 9.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.78% (Net Income 1.56b / Total Assets 18.2b)
RoE = 15.76% (Net Income TTM 1.56b / Total Stockholder Equity 9.88b)
RoCE = 16.41% (EBIT 1.96b / Capital Employed (Equity 9.88b + L.T.Debt 2.06b))
RoIC = 12.48% (NOPAT 1.68b / Invested Capital 13.4b)
WACC = 7.15% (E(49.3b)/V(51.8b) * Re(7.28%) + D(2.43b)/V(51.8b) * Rd(5.19%) * (1-Tc(0.14)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -11.11 | Cagr: -1.02%
[DCF] Terminal Value 77.97% ; FCFF base≈1.56b ; Y1≈1.79b ; Y5≈2.63b
[DCF] Fair Price = 208.3 (EV 39.6b - Net Debt -43.0m = Equity 39.6b / Shares 190.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 96.51 | Revenue CAGR: 18.19% | SUE: 0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=10.78 | Chg30d=+0.85% | Revisions=+43% | GrowthEPS=+7.9% | GrowthRev=+10.2%
EPS next Year (2027-12-31): EPS=13.62 | Chg30d=+0.08% | Revisions=+43% | GrowthEPS=+26.4% | GrowthRev=+13.1%
[Analyst] Revisions Ratio: +43%